Real‐world 52‐week effectiveness of deucravacitinib in psoriasis: A stratified analysis by age and body mass index

The Journal of Dermatology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 28, 2025

Abstract Deucravacitinib, an oral tyrosine kinase 2 inhibitor, is effective for psoriasis. However, long‐term real‐world effectiveness stratified by age and body mass index (BMI) has not been precisely examined. This study aimed to evaluate 52‐week of deucravacitinib in psoriasis patients, (≥65 years vs <65 years) BMI (≥25 <25). A prospective was conducted from December 2022 August 2024, involving 107 Japanese patients aged ≥15 with moderate severe Patients received 6 mg daily 52 weeks. Therapeutic evaluated the achievement rates Psoriasis Area Severity Index (PASI) 75, PASI 90, 100, other key clinical indices. Data were BMI. Mean scores decreased until week similarly all patients’ groups or The 100 at 86.36%, 59.09%, 13.64% ≥65 years, while they 65.22%, 39.13% respectively, showing a slightly lower rate years. 81.82%, 73.33%, 18.18% ≥25, 88.24%, 82.86%, 29.41% < 25, these weeks 4, 16, 24, 40 ≥25. Deucravacitinib improved indices during period patients' present results indicate that may be elderly as well younger middle‐aged ≥25 compared those 25.

Language: Английский

---

Long‐term real‐world effectiveness of deucravacitinib in psoriasis: A 52‐week prospective study stratified by prior apremilast or biologic therapy

The Journal of Dermatology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 7, 2025

Abstract Real‐world evidence on the long‐term effectiveness of deucravacitinib, a selective tyrosine kinase 2 inhibitor for psoriasis, remains limited, particularly in patients with different histories systemic treatments. We evaluated 52‐week deucravacitinib stratified by history apremilast or biologic usage. This prospective, single‐center study included 110 moderate‐to‐severe psoriasis who received daily (6 mg). Psoriasis Area and Severity Index (PASI) Dermatology Life Quality (DLQI) scores during treatment were analyzed subgroups Deucravacitinib decreased PASI DLQI 52 weeks patients, both without prior The percent reductions from baseline at week similar apremilast‐experienced (92% 77.9%) apremilast‐naive (88.3% 81.6%), respectively. achievement rates 100 absolute ≤1 (30.8% 61.5%) slightly higher than those (20.5% 46.2%). biologic‐naive (91.6 82.8%) biologic‐experienced (57.6% 63.6%), 75, (84.4%, 24.4%, 53.3%) (57.1%, 14.3%, 28.6%), generated sustained diverse patient subgroups, supporting its role as universal psoriasis.

Language: Английский

---

Exploring the Efficacy, Safety, and Clinical Implications of Deucravacitinib in East Asians with Psoriasis: A Narrative Review

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(5), P. 1746 - 1746

Published: March 5, 2025

Deucravacitinib, a selective oral tyrosine kinase 2 (TYK2) inhibitor, has demonstrated strong efficacy in the treatment of moderate-to-severe psoriasis. It works through an allosteric mechanism to selectively inhibit TYK2, leading suppression IL-23/Th17/IL-17 axis and reduction key pro-inflammatory cytokines such as IL-17A, IL-17F, IL-22, IL-23. This review focuses on clinical implications deucravacitinib East Asian patients, highlighting its efficacy, safety, differences outcomes compared other populations. Data from pivotal trials POETYK PSO-3 PSO-4, which included populations, robust safety profiles, often surpassing results observed global like PSO-1 PSO-2. Subgroup analyses network meta-analyses further corroborate these findings, providing comprehensive understanding therapeutic potential this demographic. Factors lower body mass index, genetic predispositions, environmental influences may contribute response. The profile is favorable, with low rates serious adverse events stable laboratory parameters. underscores need for research investigate genetic, metabolic, factors that influence outcomes, aiming optimize personalized strategies patients

Language: Английский

---

JAK Inhibitors and Inflammatory Nail Disorders: A Systematic Review of Clinical Outcomes and Therapeutic Potential

American Journal of Clinical Dermatology, Journal Year: 2025, Volume and Issue: unknown

Published: April 23, 2025

Language: Английский

---

Updates on Psoriasis in Special Areas

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(24), P. 7549 - 7549

Published: Dec. 11, 2024

Special areas of involvement in psoriasis include the scalp region, palms and soles, genital areas, as well intertriginous sites. The these topographical regions is associated with important physical emotional implications, resulting reduced quality life, social isolation, work disability. Palms soles can be affected part generalized form or exclusively palmo-plantar psoriasis. Nail may encountered 10–55% patients psoriasis, while occurs 45–56% individuals Genital only manifestation cutaneous 2–5% patients. Inverse represents a special variant it mimic difficult to differentiate from other dermatological entities that involve skin, such bacterial fungal infections, eczema, lichen planus. Treatment challenging due facts are more resistant standard therapies sensitive potent local treatments. Biological therapies, proven efficient than not widely available absence extensive skin involvement. This manuscript aims provide an up-to-date literature review on benefiting everyday clinical practice physicians optimizing evaluation treatment their

Language: Английский

---